Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca ( (GB:AZN) ) has provided an update.
AstraZeneca announced the filing of its 2024 Annual Report on Form 20-F with the US Securities and Exchange Commission, providing stakeholders access to its complete audited financial statements. This filing underscores AstraZeneca’s transparency and commitment to compliance, which can enhance trust among investors and affirm its strong position in the biopharmaceutical industry.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focusing on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are available in more than 125 countries, reaching millions of patients worldwide.
YTD Price Performance: 11.90%
Average Trading Volume: 2,726,647
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £181.6B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.